Patents by Inventor Jack Scott

Jack Scott has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9688654
    Abstract: The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK2 kinase is involved.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: June 27, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael Miller, Kallol Basu, Duane DeMong, Jack Scott, Hong Liu, Xing Dai, Andrew Stamford, Marc Poirier, Paul Tempest
  • Patent number: 9493440
    Abstract: The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: November 15, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael Miller, Kallol Basu, Duane DeMong, Jack Scott, Wei Li, Andrew Stamford, Marc Poirer, Paul Tempest
  • Patent number: 9440952
    Abstract: The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: September 13, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael Miller, Kallol Basu, Duane DeMong, Jack Scott, Hong Liu, Xing Dai, Joel M. Harris, Bernard Neustadt, Andrew Stamford, Marc Poirier, John A. McCauley, Thomas Greshock, Heather Stevenson, John Sanders, Jonathan Kern
  • Patent number: 9416126
    Abstract: The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: August 16, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael Miller, Kallol Basu, Duane DeMong, Jack Scott, Wei Li, Joel Harris, Andrew Stamford, Marc Poirier, Paul Tempest
  • Publication number: 20160009681
    Abstract: The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK2 kinase is involved.
    Type: Application
    Filed: February 27, 2014
    Publication date: January 14, 2016
    Inventors: Michael Miller, Kallol Basu, Duane DeMong, Jack Scott, Hong Liu, Xing Dai, Andrew Stamford, Marc Poirier, Paul Tempest
  • Publication number: 20160009696
    Abstract: The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
    Type: Application
    Filed: February 27, 2014
    Publication date: January 14, 2016
    Inventors: Michael Miller, Kallol Basu, Duane DeMong, Jack Scott, Wei Li, Joel Harris, Andrew Stamford, Marc Poirier, Paul Tempest
  • Publication number: 20160009682
    Abstract: The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
    Type: Application
    Filed: February 27, 2014
    Publication date: January 14, 2016
    Inventors: Michael Miller, Kallol Basu, Duane DeMong, Jack Scott, Hong Liu, Xing Dai, Joel M. Harris, Bernard Neustadt, Andrew Stamford, Marc Poirier, John A. McCauley, Thomas Greshock, Heather Stevenson, John Sanders, Jonathan Kern
  • Publication number: 20160009689
    Abstract: The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
    Type: Application
    Filed: February 27, 2014
    Publication date: January 14, 2016
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael Miller, Kallol Basu, Duane DeMong, Jack Scott, Wei Li, Andrew Stamford, Marc Poirer, Paul Tempest
  • Publication number: 20080095740
    Abstract: The present invention provides a compound of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein the various moieties are as defined in the specification. The present invention also provides pharmaceutical compositions containing the compound of this invention, and methods of treatment using the compound of this invention. The invention also relates to the use of a combination of a compound of this invention and one or more antiviral or other agents useful in the treatment of Human Immunodeficiency Virus (HIV). The invention further relates to the use of a compound of this invention, alone or in combination with another agent, in the treatment of solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis.
    Type: Application
    Filed: October 26, 2007
    Publication date: April 24, 2008
    Inventors: Michael Miller, Jack Scott
  • Publication number: 20080081160
    Abstract: A print receptive polyurethane coating is described. It is derived from a non-ionically stabilized polyurethane dispersion and an ink receptive particulate. Coatings and films for textiles and other articles and applications using such polyurethanes have been described.
    Type: Application
    Filed: September 28, 2007
    Publication date: April 3, 2008
    Applicant: LUBRIZOL ADVANCED MATERIALS, INC.
    Inventors: Gary Anderle, Jack Scott, Timothy Felmet
  • Publication number: 20070203183
    Abstract: A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, are useful in treating diseases, disorders, or conditions such as metabolic syndrome (e.g., obesity, waist circumference, lipid profile, and insulin sensitivity), neuroinflammatory disorders, cognitive disorders, psychosis, addictive behavior, gastrointestinal disorders, and cardiovascular conditions.
    Type: Application
    Filed: January 11, 2007
    Publication date: August 30, 2007
    Inventors: Jack Scott, Jay Weinstein, Michael Miller, Andrew Stamford, Eric Gilbert, Yan Xia, William Greenlee, Sarah Li
  • Publication number: 20070197628
    Abstract: A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, is useful in treating diseases, disorders, or conditions such as obesity, metabolic disorders, addiction, diseases of the central nervous system, cardiovascular disorders, respiratory disorders, and gastrointestinal disorders.
    Type: Application
    Filed: January 16, 2007
    Publication date: August 23, 2007
    Inventors: Samuel Chackalamannil, Mariappan Chelliah, Martin Clasby, Keith Eagen, Jack Scott, Yuguang Wang, Yan Xia, William Greenlee
  • Publication number: 20060241121
    Abstract: Compounds of Formula (I): or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.
    Type: Application
    Filed: December 1, 2005
    Publication date: October 26, 2006
    Inventors: William Greenlee, Jay Weinstein, Eric Gilbert, Michael Miller, Jack Scott, Andrew Stamford
  • Publication number: 20060025441
    Abstract: In its many embodiments, the present invention provides a novel class of bipiperidinyl compounds as inhibitors of the CCR5 receptors, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with CCR5 using such compounds or pharmaceutical compositions. The invention also relates to the use of a combination of a compound of this invention and one or more antiviral or other agents useful in the treatment of Human Immunodeficiency Virus (HIV). The invention further relates to the use of a compound of this invention, alone or in combination with another agent, in the treatment of solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis.
    Type: Application
    Filed: November 1, 2004
    Publication date: February 2, 2006
    Inventors: Michael Miller, Jack Scott
  • Patent number: 6686027
    Abstract: A security substrate for a document of value comprises a laminate including a generally transparent core layer and generally transparent outer layers on opposite sides of the core layer. At least one interference filter is embedded within the laminate. The interference filter includes a highly reflective opaque layer on a surface of the core layer and an optically variable thin film multilayer overlying at least a portion of the opaque layer. The interference filter is covered by one of the outer layers.
    Type: Grant
    Filed: September 25, 2000
    Date of Patent: February 3, 2004
    Assignee: Agra Vadeko Inc.
    Inventors: Omar Caporaletti, John Nicholas Disano, Jack Scott